'Prescription drugs and driving performance'

JAMA ◽  
1985 ◽  
Vol 254 (1) ◽  
pp. 15 ◽  
Author(s):  
Virginia Cowart
JAMA ◽  
1985 ◽  
Vol 254 (1) ◽  
pp. 15-15 ◽  
Author(s):  
V. Cowart

1978 ◽  
Vol 16 (17) ◽  
pp. 65-67

The Problem - Many drugs may adversely affect driving performance, athough doctors do not always warn their patients of this possibility.1 Every doctor should be familiar with possible unwanted reactions or interactions of drugs he prescribes and with the driving licence regulations, and should advise his patients accordingly. It is an offence to drive or be in charge of a vehicle when the ability to drive is impaired by drugs. A licence holder must notify any relevant or prospective disability which is likely to last more than 3 months to the Driver and Vehicle Licensing Centre. Relevant means a disability which could possibly be a source of danger to the public while driving. This article mainly deals with drugs which might impair driving but whose unwanted effects may be so unobtrusive that they are ignored by the patient. Laws relating to alcohol are not considered here. Some drugs (e.g. anticonvulsants for epilepsy)2 may make driving safer.


JAMA ◽  
1966 ◽  
Vol 195 (5) ◽  
pp. 376-379 ◽  
Author(s):  
J. G. Perry
Keyword(s):  

2015 ◽  
Vol 20 (3) ◽  
pp. 155-166 ◽  
Author(s):  
Larissa J. Maier ◽  
Michael P. Schaub

Abstract. Pharmacological neuroenhancement, defined as the misuse of prescription drugs, illicit drugs, or alcohol for the purpose of enhancing cognition, mood, or prosocial behavior, is not widespread in Europe – nevertheless, it does occur. Thus far, no drug has been proven as safe and effective for cognitive enhancement in otherwise healthy individuals. European studies have investigated the misuse of prescription and illicit stimulants to increase cognitive performance as well as the use of tranquilizers, alcohol, and cannabis to cope with stress related to work or education. Young people in educational settings report pharmacological neuroenhancement more frequently than those in other settings. Although the regular use of drugs for neuroenhancement is not common in Europe, the irregular and low-dose usage of neuroenhancers might cause adverse reactions. Previous studies have revealed that obtaining adequate amounts of sleep and using successful learning techniques effectively improve mental performance, whereas pharmacological neuroenhancement is associated with ambiguous effects. Therefore, non-substance-related alternatives should be promoted to cope with stressful situations. This paper reviews the recent research on pharmacological neuroenhancement in Europe, develops a clear definition of the substances used, and formulates recommendations for practitioners regarding how to react to requests for neuroenhancement drug prescriptions. We conclude that monitoring the future development of pharmacological neuroenhancement in Europe is important to provide effective preventive measures when required. Furthermore, substance use to cope with stress related to work or education should be studied in depth because it is likely more prevalent and dangerous than direct neuroenhancement.


Sign in / Sign up

Export Citation Format

Share Document